Volume 23, Number 1—January 2017
CME ACTIVITY - Research
Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010
Xizhong Cui1, Leisha D. Nolen1, Junfeng Sun, Malcolm Booth, Lindsay Donaldson, Conrad P. Quinn, Anne E. Boyer, Katherine A. Hendricks, Sean Shadomy, Pieter Bothma, Owen Judd, Paul McConnell, William A. Bower, and Peter Q. Eichacker
Table 4
Initial laboratory findings of AIG-IV recipients and nonrecipients, Scotland, UK, 2009–2010*
| Laboratory test [reference value] | Non-AIG-IV | AIG-IV | p value |
|---|---|---|---|
| Complete blood counts and differentials | |||
| Leukocytes, × 109 cells/L, median (IQR) [4–11 × 109/L] | 10.9 (8.6–14.1), n = 27 | 18.9 (9.5–23.2), n = 15 | 0.02 |
| Neutrophils, × 109 cells/L, median (IQR) [2–7 × 109/L] | 7.6 (5.2–10.0), n = 26 | 15.4 (7.4–19.5), n = 15 | 0.008 |
| Lymphocytes, × 109 cells/L, median (IQR) [1–3 × 109/L] | 1.8 (1.3–2.5), n = 25 | 2.0 (1.3–2.7), n = 15 | 0.78 |
| Hemoglobin, g/dL, mean ± SE [12–18 g/dL] | 14.0 ± 0.8, n = 27 | 14.8 ± 1.5, n = 15 | 0.61 |
| Hematocrit, %, mean ± SE [35%–50%] | 41 ± 2, n = 23 | 42 ± 4, n = 13 | 0.86 |
| Platelets, × 109/L, mean ± SE [150–450 × 109/L] |
214 ± 19, n = 24 |
181 ± 24, n = 15 |
0.29 |
| Coagulation parameters and C-reactive protein | |||
| Prothrombin time(s), median (IQR) [11–13.5 s] | 11.0 (10.0–14.0), n = 15 | 12.8 (12.0–15.0), n = 14 | 0.94 |
| Partial thromboplastin time(s), median (IQR) [25–35 s] | 26.7 (24.0–36.0), n = 10 | 33.8 (30.0–39.0), n = 14 | 0.63 |
| International normalized ratio, median (IQR) [0.8–1.1] | 1.1 (1.0–1.3), n = 11 | 1.1 (1.0–1.3), n = 11 | 0.36 |
| C-reactive protein, nmol/L, median (IQR) [<95 nmol/L] |
21 (8–49), n = 25 |
32 (17–52), n = 14 |
0.24 |
| Serum electrolytes and glucose | |||
| Sodium, mmol/L, median (IQR) [135–145 mmol/L] | 137 (132–139), n = 27 | 135 (131–136), n = 15 | 0.11 |
| Chloride mmol/L, median (IQR) [96–108 mmol/L] | 100 (96–101) , n = 13 | 102 (101–103), n = 14 | 0.76 |
| Potassium, mmol/L, mean ± SE [3.5–5.3 mmol/L] | 4.26 ± 0.13, n = 28 | 4.35 ± 0.22, n = 13 | 0.69 |
| Calcium, mmol/L, median (IQR) [2.25–2.5 mmol/L] | 2.3 (2.0–2.3), n = 28 | 2.1 (2.0–2.3), n = 12 | 0.97 |
| HCO3- , mmol/L, mean ± SE [22–28 mmol/L] | 24.4 ± 1.2, n = 11 | 20.7 ± 0.9, n = 11 | 0.02 |
| Glucose, mmol/L, median (IQR) [3.6–6.0 mmol/L] |
6.5 (5.6–8.1), n = 16 |
7.8 (5.3–8.9), n = 10 |
0.69 |
| Renal and liver functions | |||
| Blood urea nitrogen, mmol/L, median (IQR) [2.5–7.8 mmol/L] | 4.3 (3.7–6.0), n = 28 | 8.6 (7.1–13.9), n = 15 | 0.01 |
| Creatinine, mmol/L, median (IQR) [40–130 μmol/L] | 75.5 (64.0–89.5), n = 28 | 102.0 (84.0–189.0), n = 15 | 0.04 |
| Bilirubin, μmol/L, median (IQR) [5–17 μmol/L] | 8.0 (5.0–11.0), n = 25 | 13.5 (9.0–17.0), n = 14 | 0.02 |
| Alanine aminotransferase, U/L, median (IQR) [<50 U/L] | 18.5 (14–36.5), n = 16 | 28.0 (11.0–40.0), n = 14 | 0.69 |
| Alkaline phosphatase, U/L, median (IQR) [30–130 U/L] | 100 (74–189), n = 15 | 85 (56–97), n = 11 | 0.04 |
| Total protein, g/L, median (IQR) [60–80 g/L] | 67 (65–75), n = 12 | 46 (41–62), n = 13 | 0.001 |
| Albumin, g/L, mean ± SE [35–55 g/L] | 38.3 ± 1.1, n = 25 | 27.6 ± 2.6, n = 14 | <0.0001 |
*n values indicate no. patients for whom data were available. Bold indicates significant differences between AIG-IV recipients and nonrecipients. AIG-IV, anthrax immune globulin intravenous; IQR, interquartile range.
1These authors contributed equally to this article.
Page created: December 14, 2016
Page updated: December 14, 2016
Page reviewed: December 14, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.